Recently, ProteinT's Series A financing was officially closed, with CDH Baifu, a leading domestic institution, as the sole investor. Following the investment of nearly RMB 100 million, the Company's long-cultivated clinical multi-omics technology advantages will be unlocked. Combined with CDH Baifu's extensive resources in the biotechnology field, ProteinT has officially entered a fast lane of rapid development. In the future, ProteinT's business and strategic footprint is expected to expand rapidly, with greater efforts devoted to the translation of innovative technologies, enabling more diseases to be detected early and treated effectively, and contributing to the clinical application of multi-omics and the advancement of precision medicine in China.
ProteinT is one of the earliest high-tech enterprises to bring multi-omics technologies to the clinic. Founded in 2014 by Dr. Li Jie after his return to China, the Company has always focused on clinical needs, introducing proteomics and metabolomics on top of genomics. Through "gene + protein + metabolism," it delivers a systematic and comprehensive understanding, overcomes the shortcomings of genomics alone, and brings more precise and even individualized clinical solutions to medicine. To date, ProteinT has established an intellectual property portfolio across seven modules—sample preparation, auxiliary materials, mass spectrometry detection, data analysis, and clinical application—and possesses full-process quality control capabilities. Leveraging its rich reserves of technology and capability and focusing on clinical needs, ProteinT has accumulated extensive clinical sample cases, continuously developed innovative clinical solutions, and carried out clinical applications through its medical laboratory. Multiple products have now successively entered the registration filing process, bringing more possibilities for early screening and precise diagnostic and therapeutic guidance for patients with cancer and cardiovascular and cerebrovascular diseases.
ProteinT
It is precisely this research and insight into the biotechnology field that brought CDH Baifu and ProteinT together. Starting from this point, the two parties will establish a long-term, close partnership to support ProteinT in rapidly expanding its technology accumulation and footprint in the clinical multi-omics field, engage in exchanges and cooperation with CDH Baifu's upstream and downstream biomedical portfolio, and drive the early clinical application of more innovative technologies.
In the post-genomic era, proteomics will become one of the most effective approaches for identifying disease molecular markers and drug targets. ProteinT has also pioneered the combination of proteomics and liquid biopsy. Using its proprietary n-LAPE/MS™ method, it has achieved more than a 10-fold increase in the number of blood proteins identified, overcome the bottleneck in blood proteomics research, and reached an internationally leading level, promising new opportunities for the early diagnosis and treatment of cancer, cardiovascular and cerebrovascular diseases, and more. At present, ProteinT's R&D pipeline covers common cancers such as lung cancer and liver cancer, and several products have begun pre-registration preparation. Going forward, the Company will accelerate its investment process and strategic cooperation in this field as opportunities arise.
How to truly let technological innovation lead medical development—from insight into clinical needs to innovative technological solutions and clinical application—is what ProteinT has always focused on and put into practice. After partnering with CDH Baifu, ProteinT will continue to uphold its original aspiration and mission of "continuously creating market demand and continuously advancing medicine," delivering ever more precise, convenient, and accessible clinical solutions so that humanity can better cope with various diseases!
About ProteinT
ProteinT is a national high-tech enterprise focusing on the frontier multi-omics field of precision medicine. It is the lead unit of the Tianjin Key Laboratory of Clinical Multi-omics, conducting research on gene + protein + metabolism multi-omics as well as advanced proprietary protein mass spectrometry liquid biopsy technology. Its core team comes from renowned research institutions at home and abroad, including Yale University, the U.S. National Institutes of Health, and the National Center for Protein Sciences. The Company's R&D pipeline covers early screening and early diagnosis, recurrence monitoring, and companion diagnostic services for common cancers and pan-cancers—such as liver cancer, lung cancer, gastric cancer, esophageal cancer, colorectal cancer, and pancreatic cancer—as well as cardiovascular and cerebrovascular diseases. It possesses the proprietary Umbrella™ clinical molecular database with more than 100,000 clinical sample data records. ProteinT is committed to continuously innovating medical technologies and their commercialization and clinical application, advancing medicine, and exploring more possibilities for human health.
About CDH Baifu
Founded in 2012, CDH Baifu is a professional boutique fund investment platform under CDH Investments focused on technology investment. It invests around the strategies of embracing new trends, expanding regions, and going against the cycle, and has systematically positioned itself in fields such as semiconductors, high-end equipment, biomedicine, carbon neutrality, and technology going global. It has invested in more than 130 projects, with assets under management exceeding RMB 70 billion. It cultivates the value chain of the industry, provides diversified asset allocation, and always maintains a spirit of hard work to create long-term value.
